Deltex Medical Group Plc Interview. Stepping up growth in USA with revenues over 40%

Nigel Keen, Chairman of Deltex Medical, commented: “The successful £2,050,000 fund raising in February 2018 has put the Group in a stronger financial position – allowing us to improve our business structure. “We made a number

Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring, the Group’s Chairman, Nigel Keen, will make the following statement at the Annual General Meeting: Hospitals in the developed world are facing increasing pressure

Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring, announced today that Ewan Phillips has resigned as Chief Executive and as a Director of the Company with immediate effect. Mr. Phillips recently approached Deltex’s

May 28th saw Deltex Medical Group supporting Current Initiatives, Research and the Role of Haemodynamic Monitoring at London’s Montague Hotel. Held under the auspices of the EBPOM organisation (Evidence Based PeriOperative Medicine), the congress saw keynote presentations from

Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring, today gives notice that its Annual Report and Accounts for the year ended 31 December 2017 has been published on the “Annual & Interim Reports”

Nigel Keen, Chairman of Deltex Medical, commented: “The progress made towards operating cash breakeven and profitability through improved consumable margins and reduced overheads made during 2017 was partially offset by a disappointing second half sales performance.

It takes a plethora of products and people to provide patients premium protection. Changing payment models, the digitization of healthcare and the need to deliver higher quality care at a lower cost are driving significant change